The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?

Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!

In high-grade #ovariancancer
The magnitude of benefit from olaparib may be related to the location of the mutation in BRCA1/2 🧬🧬
@Annals_Oncology @myESMO @OncoAlert @VJOncology @ESGO_society @acog @ASCO @agz_eriksson @IGCSociety @SGO_org @VukovicPetra
https://doi.org/10.1016/j.annonc.2022.11.003